Amylyx Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.00 | -$0.00 | -$0.00 |
| Q2 2024 | 1 | -$0.73 | -$0.73 | -$0.73 |
| Q3 2024 | 1 | -$0.70 | -$0.70 | -$0.70 |
| Q4 2024 | 1 | -$0.59 | -$0.53 | -$0.56 |
| Q1 2025 | 1 | -$0.64 | -$0.64 | -$0.64 |
| Q2 2025 | 1 | -$0.66 | -$0.66 | -$0.66 |
| Q3 2025 | 1 | -$0.66 | -$0.66 | -$0.66 |
| Q4 2025 | 1 | -$0.62 | -$0.62 | -$0.62 |
Amylyx Pharmaceuticals, Inc. Earnings Date And Information
Amylyx Pharmaceuticals, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.53 earnings per share for the quarter, missing analysts' consensus estimates of $-0.47 by $0.06. The company had revenue of 416,000 for the quarter and had revenue of 380.79 M for the year. Amylyx Pharmaceuticals, Inc. has generated $1 earnings per share over the last year ($0.7 diluted earnings per share) and currently has a price-to-earnings ratio of -1.38. Amylyx Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Amylyx Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.47 | -$1.07 | -0.6 | $31.57 M | $416,000 |
| 08/08/2024 | Q2 2024 | -$0.38 | -$1.07 | -0.69 | $10.66 M | $-1,022,999 |
| 05/09/2024 | Q1 2024 | $0.24 | -$1.75 | -1.99 | $88.64 M | |
| 02/22/2024 | Q4 2023 | $0.23 | $0.07 | -0.16 | $108.45 M | |
| 11/09/2023 | Q3 2023 | $0.44 | $0.31 | -0.13 | $113.66 M | $102.69 M |
| 08/10/2023 | Q2 2023 | $0.10 | $0.33 | 0.23 | $92.21 M | $98.22 M |
| 05/11/2023 | Q1 2023 | -$0.24 | $0.02 | 0.26 | $71.43 M | |
| 03/13/2023 | Q4 2022 | -$0.65 | $21.89 M | |||
| 11/10/2022 | Q3 2022 | -$0.97 | -$0.92 | 0.05 | $83,333 | $345,000 |
| 08/11/2022 | Q2 2022 | -$0.92 | -$0.93 | -0.01 | $125,000 | $0 |
| 05/12/2022 | Q1 2022 | -$0.75 | -$0.93 | -0.18 | $0 | |
| 03/31/2022 | Q4 2021 | -$0.51 | $0 | |||
| 09/30/2021 | Q3 2021 | -$0.42 | $285,000 | |||
| 06/30/2021 | Q2 2021 | -$0.48 | $0 | |||
| 03/31/2021 | Q1 2021 | -$0.32 | $0 | |||
| 12/31/2020 | Q4 2020 | -$0.19 | $350,000 |
Amylyx Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Amylyx Pharmaceuticals, Inc.'s earnings date?
Amylyx Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
-
How can I listen to Amylyx Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Amylyx Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Amylyx Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Amylyx Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Amylyx Pharmaceuticals, Inc. generate each year?
Amylyx Pharmaceuticals, Inc. (:AMLX) has a recorded annual revenue of $380.79 M.
-
How much profit does Amylyx Pharmaceuticals, Inc. generate each year?
Amylyx Pharmaceuticals, Inc. (:AMLX) has a recorded net income of $380.79 M. Amylyx Pharmaceuticals, Inc. has generated $0.73 earnings per share over the last four quarters.
-
What is Amylyx Pharmaceuticals, Inc.'s price-to-earnings ratio?
Amylyx Pharmaceuticals, Inc. (:AMLX) has a price-to-earnings ratio of -1.38 and price/earnings-to-growth ratio is 0.02.
